Summit Therapeutics Set to Announce Q4 Earnings on February 23
Summit Therapeutics (SMMT) is scheduled to release its Q4 earnings on February 23, with an expected EPS of -$0.02, signaling a significant year-over-year improvement. Despite historical challenges in meeting revenue estimates, the stock has seen a spike and rating upgrades due to its lead asset undergoing FDA review, suggesting cautious market optimism. Analysts have mixed views, with some revising EPS estimates upward while revenue estimates have faced a downward revision.
Preview: Summit Therapeutics's Earnings
Summit Therapeutics (NASDAQ: SMMT) is set to release its quarterly earnings report on Monday, February 23, 2026, with analysts projecting an earnings per share (EPS) of $-0.11. Investors are closely watching for the company's performance against estimates and future guidance. Historically, the company missed its previous EPS estimate, leading to a share price drop, and its shares have been down 15.76% over the last 52 weeks.
Skandinaviska Enskilda Banken AB publ Has $6.99 Million Holdings in Summit Therapeutics PLC $SMMT
Skandinaviska Enskilda Banken AB publ significantly increased its stake in Summit Therapeutics PLC, adding 271,912 shares to now hold 338,363 shares valued at $6.99 million. Other institutional investors also adjusted their positions, though hedge funds and institutions collectively own a small percentage of the stock. Summit Therapeutics currently has a "Moderate Buy" consensus rating from analysts with an average price target of $33.08.
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) announced it will host an earnings call to report its fourth quarter and full year 2025 financial results and provide an operational update. The call is scheduled for Monday, February 23, 2026, at 4:30 PM ET, after the market closes, and will be accessible via a live webcast on the company's website. Summit Therapeutics, a biopharmaceutical oncology company, focuses on developing medicinal therapies to improve quality and duration of life for patients.
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) will host an earnings call on Monday, February 23, 2026, after market close, to discuss its fourth quarter and full year 2025 financial results and provide an operational update. A live webcast of the call will be accessible at 4:30 PM ET on the company's website, www.smmttx.com, with an archived version available afterward. Summit Therapeutics is an oncology biopharmaceutical company focused on developing medicinal therapies to improve patient quality of life.
Precision Trading with Summit Therapeutics Inc. (SMMT) Risk Zones
This article provides a precision trading analysis for Summit Therapeutics Inc. (SMMT) with a focus on risk zones. It highlights a strong near-term sentiment potentially challenging mid and long-term weakness and offers three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis includes entry zones, target prices, and stop losses, informed by multi-timeframe signal analysis.
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) will host an earnings call on Monday, February 23, 2026, after market close, to discuss its fourth quarter and full year 2025 financial results and provide an operational update. A live webcast of the conference call will be accessible at 4:30 PM ET via their website, www.smmttx.com, with an archived edition available subsequently. Summit Therapeutics is an oncology biopharmaceutical company focused on developing medicinal therapies to improve quality and duration of life for patients.
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough
Summit Therapeutics (SMMT) is garnering investor attention following the FDA's acceptance of its ivonescimab lung cancer treatment application, targeting a significant market gap. The company, which is focused on oncology therapies, has received mostly bullish ratings from analysts, with a substantial projected one-year price target. The decision date for the ivonescimab application, which is supported by Phase III trial data, is set for November 14, 2026.
Summit Therapeutics (SMMT) to Release Earnings on Monday
Summit Therapeutics (SMMT) is scheduled to release its Q4 2025 earnings before market open on Monday, February 23rd, with analysts expecting a ($0.27) loss per share and $75.47 million in revenue. The company's shares opened at $14.96, trading within a 1-year range of $13.83–$36.91, and have a market capitalization of $11.54 billion. Analyst sentiment is generally positive, with a "Moderate Buy" consensus rating and an average price target of $33.62.
A Look At Summit Therapeutics (SMMT) Valuation After FDA Acceptance Of Ivonescimab BLA
Summit Therapeutics (SMMT) recently received FDA acceptance for its Biologics License Application for ivonescimab, leading to a 5.8% share price increase over seven days, despite a 10.5% decline over 30 days. The company's high Price-to-Book ratio of 61.2x suggests optimistic investor expectations for future potential, rather than current financials, as it operates at a net loss. While the P/B indicates overvaluation, a discounted cash flow model suggests a much higher per-share value, highlighting divergent valuation perspectives.
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In?
H.C. Wainwright reaffirmed a Buy rating on Summit Therapeutics Inc. (SMMT) with a $40 price target, following the FDA's acceptance of the Biologics License Application for ivonescimab for EGFR-mutated NSCLC. The firm sees this as a significant de-risking event, with a potential U.S. approval decision by November 2026. The valuation is based on a discounted cash flow model supporting a $40 per share target.
FDA accepts Summit Therapeutics’ (SMMT) BLA for ivonescimab in NSCLC with November 14 PDUFA date following positive phase III data
The FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab for treating non-small cell lung cancer (NSCLC). This decision follows strong positive results from two Phase III studies conducted in China, and a PDUFA date has been set for November 14. The drug is being developed in collaboration with Akeso and has shown promising efficacy in this patient population.
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In?
H.C. Wainwright recently reaffirmed a Buy rating on Summit Therapeutics Inc. (SMMT) with a $40 price target, following the FDA's acceptance of the Biologics License Application for ivonescimab, setting a potential U.S. approval date by November 2026. The firm's valuation, based on a discounted cash flow model, suggests significant upside, driven by confidence in the ivonescimab data and PD-1 as a target. While Summit Therapeutics, a biopharmaceutical company, shows growth potential, the article suggests that other AI stocks might offer better returns with limited downside risk.
Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date
Summit Therapeutics' stock (SMMT) rose 6.5% after the FDA accepted its Biologics License Application (BLA) for ivonescimab in EGFR-mutated non-small cell lung cancer, setting a PDUFA date of November 14, 2026. This milestone provides a clearer regulatory path and integrates ivonescimab into several oncology indications through trials and collaborations. The company's future is closely tied to ivonescimab's clinical and regulatory success, making it a high-risk, high-reward investment.
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential
Summit Therapeutics' Biologics License Application for ivonescimab has been accepted by the FDA for EGFR mutated non-small cell lung cancer, marking a key step in its regulatory journey. The company has several ongoing late-stage clinical trials, and early results suggest potential for ivonescimab beyond lung cancer, including colorectal cancer. With a PDUFA goal date of November 14, 2026, the company's focus is shifting towards late-stage regulatory execution and commercialization.
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Analysts have issued a "Moderate Buy" consensus recommendation for Summit Therapeutics PLC (NASDAQ:SMMT) from 17 firms, with an average one-year target price of $33.62. The company, a clinical-stage biotech developing ridinilazole for C. difficile, has seen its shares trading up 8.2% at $14.99 and has a market capitalization of $11.56 billion. Institutional ownership stands at approximately 4.61%, with recent significant investments like Apeiron Capital's new $25.6 million stake.
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential
Summit Therapeutics' Biologics License Application for ivonescimab has been accepted by the FDA, initiating a formal review process with a PDUFA goal date of November 14, 2026. This development, along with ongoing Phase III trials for NSCLC and colorectal cancer, shifts the company's focus towards late-stage execution and potential commercialization. While the BLA acceptance provides a clear regulatory timeline and potential value inflection points, Summit Therapeutics remains unprofitable and highly dependent on external funding, making future trial readouts and regulatory decisions critical catalysts.
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research
Zacks Research has downgraded Summit Therapeutics (NASDAQ:SMMT) from a "hold" to a "strong sell" rating. Despite this, the company still holds a consensus "Moderate Buy" rating with a target price of $33.62 from other analysts, significantly higher than its current trading price of around $13.85. The article also notes recent institutional trading activity and provides a company profile for Summit Therapeutics, highlighting its focus on precision medicines.
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com
Summit Therapeutics PLC's stock recently hit a new 52-week low, closing at $14.01, representing a 31.69% decrease over the past year due to challenges in the biotechnology sector. Despite this downturn, the company has received positive attention for the FDA's acceptance of its Biologics License Application (BLA) for ivonescimab, a treatment for EGFR-mutated non-small cell lung cancer, with a PDUFA goal date of November 14, 2026. H.C. Wainwright and Citizens have reiterated Buy and Market Outperform ratings, respectively, maintaining a $40.00 price target for the company.
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data
The FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab, in combination with chemotherapy, for the treatment of EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed after TKI therapy. A PDUFA date of November 14, 2026, has been set for a regulatory decision. The submission is backed by positive Phase III HARMONi study data, addressing a significant unmet medical need for over 14,000 U.S. patients annually.
Is Summit Therapeutics (SMMT) Pricing In Too Much Hope After Recent Share Price Swings?
This article analyzes Summit Therapeutics (SMMT) stock performance and valuation. Despite recent declines, the stock has shown significant long-term growth. Using a Discounted Cash Flow (DCF) analysis, the article suggests SMMT is significantly undervalued, while a Price-to-Book (P/B) ratio indicates it might be overvalued compared to its fair ratio.
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com
Summit Therapeutics PLC's stock recently hit a 52-week low, closing at 14.01 USD, representing a 31.69% decrease over the past year. This downturn comes despite positive news regarding the FDA's acceptance of its Biologics License Application (BLA) for ivonescimab, targeting EGFR-mutated non-small cell lung cancer, with a PDUFA goal date of November 14, 2026. H.C. Wainwright and Citizens have reiterated Buy/Market Outperform ratings with a $40.00 price target, signaling continued analyst confidence despite market pressures.
Summit Therapeutics stock hits 52-week low at 14.01 USD
Summit Therapeutics PLC's stock recently reached a new 52-week low of 14.01 USD, reflecting a 31.69% decrease over the past year due to challenges in the biotechnology sector. Despite this downturn, the company has received positive attention from analysts at H.C. Wainwright and Citizens, who reiterated Buy and Market Outperform ratings, respectively, after the FDA accepted its Biologics License Application for ivonescimab for lung cancer treatment. The FDA has set a PDUFA goal action date of November 14, 2026.
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data
The FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for treating EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. The PDUFA goal action date for a regulatory decision is November 14, 2026. This submission is supported by positive data from the Phase III HARMONi global study, targeting a significant unmet medical need in the US.
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data
The FDA has accepted Summit Therapeutics' (SMMT) Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The PDUFA goal date for a regulatory decision is November 14, 2026. This submission is supported by positive data from the Phase III HARMONi study, highlighting ivonescimab's potential as a bispecific antibody to address an unmet need in this patient population.
Assessing Summit Therapeutics (SMMT) Valuation After FDA Acceptance Of Ivonescimab BLA
Summit Therapeutics (SMMT) recently had its Biologics License Application for ivonescimab accepted by the FDA, with a PDUFA action date set for November 14, 2026. Despite a high Price-to-Book ratio of 58.5x, suggesting overvaluation compared to industry peers, Simply Wall St's Discounted Cash Flow model indicates a significant undervaluation at $14.59 per share against an estimated future cash flow value of $213.88. Investors face a mixed signal from the market, with recent share price declines contrasting with long-term returns and a projected large discount based on future cash flow.
Summit Therapeutics (SMMT) Stock Analysis: A Potential 128% Upside In Biotech
Summit Therapeutics (SMMT) is analyzed as a high-risk, high-reward investment in the biotechnology sector, with a potential 128% upside according to analyst ratings. Based in Miami, Florida, the company is developing ivonescimab for non-small cell lung cancer, which is currently in Phase III trials. Despite negative EPS and ROE, the company shows a positive free cash flow, suggesting financial health, while technical indicators hint at it being undervalued.
H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock
H.C. Wainwright has reiterated a Buy rating and a $40.00 price target for Summit Therapeutics (NASDAQ:SMMT) after the FDA accepted its Biologics License Application (BLA) for ivonescimab. This BLA acceptance for EGFR-mutated non-small cell lung cancer is considered a significant risk-mitigating event, with the FDA setting a PDUFA action date of November 14, 2026. Other firms like Citizens and Cantor Fitzgerald also maintain positive outlooks, citing the company's clinical progress and upcoming phase 3 study.
Summit Therapeutics stock gets FDA acceptance for ivonescimab BLA
Summit Therapeutics (NASDAQ:SMMT) announced that the FDA has accepted its Biologics License Application (BLA) for ivonescimab for EGFR-mutated non-small cell lung cancer. The FDA has set a PDUFA date of November 14, 2026, and analysts maintain a bullish outlook with price targets suggesting potential upside, despite a recent stock dip. The company has a strong cash position and multiple Phase 3 trials underway for ivonescimab, with results anticipated in 2026 and 2027.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Inc. announced the grant of inducement awards consisting of options to purchase up to 257,368 shares of common stock. These awards were made to 20 new employees as an inducement to join the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The options, granted on January 26, 2026, have a ten-year term, an exercise price of $16.56 per share, and vest in equal annual installments over four years.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Therapeutics Inc. announced inducement awards of options to purchase 257,368 shares of common stock to 20 new employees. The awards were granted on January 26, 2026, with an exercise price of $16.56 per share, as an inducement for new hires under Nasdaq Listing Rule 5635(c)(4). These options have a ten-year term and vest in equal annual installments over a four-year period.
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
Summit Therapeutics announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed after TKI therapy. The application is based on positive results from the HARMONi global Phase III study, and the FDA has set a PDUFA goal action date of November 14, 2026. This approval, if granted, would address a significant unmet need for over 14,000 U.S. patients annually.
Reassessing Summit Therapeutics (SMMT) After Sharp Pullback And DCF Upside Potential
Summit Therapeutics (SMMT) has experienced significant share price volatility, with recent declines despite strong longer-term gains. A Discounted Cash Flow (DCF) analysis suggests the stock is 93.0% undervalued, with an estimated intrinsic value of $218.48 per share compared to its current price of US$15.40. However, its Price-to-Book (P/B) ratio of 61.77x is considerably higher than industry and peer averages, indicating it might be overvalued by this metric.
FDA Accepts Summit Therapeutics' BLA for Ivonescimab
The FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab, in combination with chemotherapy, for EGFR-mutated advanced non-small cell lung cancer, with a decision expected by November 14, 2026. This acceptance is based on promising Phase 3 HARMONi trial results, which showed a median overall survival benefit. Summit Therapeutics plans to expand ivonescimab's clinical development through ongoing and new trials, including for metastatic colorectal cancer, highlighting its potential to address significant unmet medical needs.
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway
The FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab, a lung cancer drug, in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer. The FDA set a PDUFA goal action date of November 14, 2026, for the review, which includes mid-cycle and wrap-up meetings. The BLA is supported by results from the Phase 3 HARMONi trial, which showed positive outcomes for ivonescimab.
Summit Therapeutics’ Ivonescimab BLA Accepted by FDA
Summit Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer. The application, supported by the HARMONi trial results, has a PDUFA goal date of November 14, 2026, and targets a significant unmet medical need. Ivonescimab is a bispecific antibody already commercialized in China, with Summit aiming to enter the U.S. oncology market.
Summit Therapeutics stock rises after FDA accepts BLA for lung cancer drug
Summit Therapeutics' stock increased by 7% after the FDA accepted its Biologics License Application (BLA) for ivonescimab, a lung cancer drug. The drug, which combines PD-1 blockade with anti-angiogenesis effects, is intended to treat EGFR-mutated non-small cell lung cancer in patients who have received prior tyrosine kinase inhibitor therapy. The FDA has set November 14, 2026, as the Prescription Drug User Fee Act (PDUFA) goal action date for the application.
Summit Therapeutics (SMMT) Gains After FDA Accepts Key Cancer Dr
Summit Therapeutics (SMMT) saw a 5% premarket stock increase after the FDA accepted its Biologics License Application for ivonescimab, a treatment for advanced non-small cell lung cancer. Despite this positive development and a notable insider ownership, the company faces financial challenges including zero revenue, negative earnings, and low profitability, alongside high stock volatility. Investors are advised to consider both the clinical progress and the company's financial health, with analyst recommendations suggesting a hold position.
Summit spikes as lead asset gets FDA review (SMMT:NASDAQ)
Summit Therapeutics (SMMT) shares rose by approximately 5% in premarket trading after the U.S. FDA accepted its Biologics License Application (BLA) for ivonescimab. This lead asset was developed in collaboration with its Chinese partner Akeso (AKESF). The BLA is currently under review by the FDA.
FDA accepts Summit Therapeutics BLA for lung cancer drug ivonescimab
The FDA has accepted Summit Therapeutics' Biologics License Application (BLA) for ivonescimab, a lung cancer drug, in combination with chemotherapy for EGFR-mutated non-small cell lung cancer patients. A Prescription Drug User Fee Act goal action date of November 14, 2026, has been set. The submission is based on positive Phase III HARMONi trial results, and the drug has already received marketing authorization in China.
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
Summit Therapeutics announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ivonescimab, in combination with chemotherapy, for patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed after TKI therapy. The application is based on positive results from the Phase III HARMONi trial, and the FDA has set a PDUFA goal action date of November 14, 2026. Ivonescimab is a novel bispecific antibody designed to target both PD-1 and VEGF, addressing a significant unmet medical need for over 14,000 U.S. patients annually.
Summit Therapeutics Inc FDA Accepts Ivonescimab BLA for NSCLC Treatment
Summit Therapeutics Inc. announced that the FDA has accepted its Biologics License Application (BLA) for ivonescimab, a treatment for EGFR-mutated non-small cell lung cancer (NSCLC) following TKI therapy. The FDA has set a PDUFA goal action date of November 14, 2026, for this application, which is based on positive results from the Phase III HARMONi trial. This treatment modality combines PD-1 and VEGF blockade and is estimated to be applicable to over 14,000 U.S. patients annually.
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive
Summit Therapeutics (NASDAQ: SMMT) is receiving positive analyst attention due to encouraging guidance on its ivonescimab clinical program and the submission of its first Biologics License Application (BLA). H.C. Wainwright and Citizens both maintained Buy/Market Outperform ratings with a $40 price target, citing potential for significant upside. The company is actively developing ivonescimab for medical oncology, including non-small cell lung cancer, and is collaborating with GSK to expand its utilization.
Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive
Summit Therapeutics (SMMT) is receiving optimistic analyst ratings, including a Buy rating from H.C. Wainwright with a $40 price target, following the submission of its Biologics License Application (BLA) for the ivonescimab clinical program. Citizens also maintained a Market Outperform rating based on the BLA submission and a new collaboration with GSK. The company, focused on oncology therapies and ivonescimab, is currently in Phase III clinical trials for non-small lung cancer.
Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative?
Summit Therapeutics is focusing its pipeline on ivonescimab, which is moving towards potential FDA approval for EGFR-mutated non-small cell lung cancer and is also being tested in combination with GSK's B7-H3-targeting ADC for solid tumors. These developments, particularly the Biologics License Application (BLA) filing, are critical near-term catalysts for the company, as its investment narrative heavily relies on ivonescimab becoming a significant oncology franchise despite current large losses and no revenue. The company faces concentration risk, as setbacks in ivonescimab's development could have significant negative impacts on its valuation and funding options.
Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative?
Summit Therapeutics' ivonescimab is at the center of new developments, including an FDA Biologics License Application filing for EGFR-mutated lung cancer and a clinical trial collaboration with GSK. These steps highlight ivonescimab as Summit's primary asset, potentially leading to US approval and broader oncology combinations, despite the company's current lack of revenue and large losses. The initiatives aim to establish a broad, combination-focused immuno-oncology platform, but also carry concentration risk due to the reliance on this single asset.
Will Ivonescimab’s FDA Filing and GSK Combo Trial Redefine Summit Therapeutics’ (SMMT) Core Narrative?
Summit Therapeutics has entered a clinical trial collaboration with GSK for ivonescimab in solid tumors and simultaneously submitted an FDA Biologics License Application for ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer. These actions solidify ivonescimab as Summit's central asset, pursuing both regulatory approval and broader oncology applications with a major partner, but highlight significant concentration risk due to the company's lack of revenue and large losses. The BLA filing is a key near-term catalyst, while the GSK collaboration offers scientific validation.
A Look At Summit Therapeutics (SMMT) Valuation After Ivonescimab FDA Filing And New GSK Collaboration
Summit Therapeutics (SMMT) has attracted renewed attention following an FDA Biologics License Application for ivonescimab in EGFR-mutated non-small cell lung cancer and a new clinical collaboration with GSK. Despite a 28.36% decline in its stock over the last year, its 67.6x Price-to-Book ratio is significantly higher than industry averages, suggesting strong market expectations for future drug approvals. However, a Discounted Cash Flow model indicates the shares might be trading at a 92.2% discount to their estimated future cash flow value, proposing a potential undervaluation based on this metric.
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab’s Expanding Reach?
Summit Therapeutics (SMMT) is advancing its oncology platform with ivonescimab, specifically through a Biologics License Application (BLA) to the FDA for its use with chemotherapy in EGFR-mutated non-small cell lung cancer, and a new collaboration with GSK for combination trials. These developments broaden ivonescimab's clinical application and position Summit as a stronger player in combination oncology therapies. Despite the positive clinical progress, the company faces risks associated with being a single-asset-dependent, loss-making entity with a high valuation.
Is Summit Therapeutics (SMMT) Building a Durable Oncology Combination Platform With Ivonescimab’s Expanding Reach?
Summit Therapeutics (SMMT) is advancing its oncology platform with important developments for its drug ivonescimab. The company has filed a Biologics License Application (BLA) with the FDA for ivonescimab combined with chemotherapy to treat EGFR-mutated non-squamous non-small cell lung cancer, creating a clear short-term catalyst. Additionally, Summit has partnered with GSK to explore ivonescimab combinations for various solid tumors, broadening its long-term potential beyond a single indication.
